Can SLS titanium parts be used as implants, and what post-processing?

Yes, titanium parts made by metal laser powder bed fusion can be used in implants, but Ti-6Al-4V ELI and post-processing alone do not make a device implantable. In buyer terminology, titanium SLS usually means PBF-LB/M processes such as SLM or DMLS, not polymer SLS. Release requires a device-specific material specification, validated build and post-processing routes, cleaning, biological evaluation, sterilization, packaging, mechanical verification, and the applicable regulatory pathway. A prototype from the same CAD file is not equivalent to a released implant. The RFQ should state intended use, body-contact category and duration, jurisdiction, device classification, and who owns each validation and release activity. Critical interfaces may also require Ti-6Al-4V ELI CNC machining under the controlled device route.

Material and process requirements for implant use

Implant use begins with the exact alloy and manufacturing specification, not a general claim of medical-grade titanium. ASTM F3001-14(2021) addresses Ti-6Al-4V ELI made by powder bed fusion. ASTM F136 and ISO 5832-3 are established references for wrought Ti-6Al-4V ELI and should not be cited as proof that an additive route is qualified. The device file must control chemistry, interstitial limits, powder-lot identity, contamination, storage, sampling, reuse rules, and certificates. Powder conformity still does not establish finished-device biocompatibility, because build exposure, support removal, surface treatment, cleaning, packaging, and sterilization can change the final surface presented to tissue.

The PBF-LB/M process must be validated over the operating range used for the device. Relevant controls include machine state, atmosphere, build location, orientation, support strategy, layer and scan parameters, powder handling, heat history, and change control. Evidence should represent the actual feature thickness, porous zones, fatigue-critical transitions, surface state, and build direction. Depending on risk, validation may include chemistry, density or metallography, tensile and fatigue testing, dimensional inspection, surface characterization, and qualified NDT or CT. A polished tensile coupon cannot release an implant with rough lattice struts, support scars, threaded interfaces, or defects below an unverified detection limit.

Post-processing for 3D-printed titanium implants

Post-processing must produce the specified microstructure, geometry, surface function, and cleanliness without hiding an unqualified build. Stress relief reduces residual stress; heat treatment sets the intended material condition; hot isostatic pressing can reduce suitable internal porosity. HIP does not remove surface-connected discontinuities, correct chemistry, clean residual powder, or prove fatigue performance. The qualified sequence may include plate separation, support removal, thermal processing, and titanium CNC machining service for tapers, threads, bearing faces, screw seats, and inspection datums. Fine finishing or electropolishing for precision parts may suit selected accessible surfaces when dimensional change, chemistry, residual stress, and surface acceptance are validated for that device.

Different implant regions may require opposite surface strategies. A bearing, sealing, or mating surface may need controlled smoothness, while a bone-contact lattice may require defined roughness or porosity. Blasting, chemical treatment, or laser texturing can modify those regions, but a rough surface also retains particles and process residue more readily. Cleaning validation must address residual powder, machining coolant, abrasive media, chemicals, particles, and biological contamination on the final geometry. Sterilization controls viable microorganisms; it does not remove chips, endotoxin, cleaning residue, or trapped powder. Final rinsing, drying, packaging, sterilization, and shelf-life evidence must therefore follow a sequence that preserves the validated surface and package integrity.

Quality systems, testing, and certification

An implantable titanium AM part is a medical-device configuration, not simply a titanium component with a certificate. ISO 13485 supports a medical-device quality management system, while ISO 14971 defines a risk-management process; neither standard certifies a specific implant by itself. FDA guidance for additive manufactured medical devices addresses design files, software workflow, material controls, process validation, post-processing, testing, and device description. ISO 10993-1 is a risk-based biological evaluation framework rather than a fixed checklist. The evidence selected depends on material and processing information, contact type, contact duration, patient exposure, and identified biological risks.

Market access is device- and jurisdiction-specific. In the United States, the applicable route may involve 510(k), De Novo, PMA, IDE activities, or another regulatory determination. In the European Union, CE marking under the Medical Device Regulation requires the applicable conformity assessment and technical documentation. Mechanical, wear, corrosion, biological, cleaning, sterilization, packaging, software, and clinical evidence depend on intended use and risk. Patient-matched devices add controls for imaging data, design transfer, build orientation, acceptance of each configuration, labeling, and traceability. A supplier's ability to print titanium or hold a QMS certificate is not evidence that the requested implant has been cleared, approved, or released.

Titanium PBF is suitable for an implant program only when material, build, post-processing, surface, cleaning, biological, sterilization, packaging, and regulatory evidence form one controlled file. The RFQ should identify the device status, alloy and AM specification, powder traceability, approved parameter set, orientation, thermal route, HIP requirement, machined and bone-contact surfaces, residue and particle limits, inspection plan, sterilization and packaging responsibility, change-control rules, and final release authority. If those controls are absent, the part should remain an R&D model, surgical-planning aid, test coupon, or non-implant component. Procurement should resolve the documentation and responsibility split before treating any printed titanium geometry as implantable.